Gene therapy for wet AMD: 4-Year safety check begins
NCT ID NCT06817343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks the long-term safety of a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (AMD), a condition that can cause severe vision loss. Participants already received the gene therapy in an earlier study and will be monitored for up to 4 years for side effects and any changes in vision. The goal is to see if the treatment is safe enough to test in more patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Sierra Eye Associates
Reno, Nevada, 89502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy tame wet AMD for years?
- Laser zap before eye injection could cut needle count for wet AMD
- New eye injection shows promise for wet AMD in everyday practice
- New syringe could simplify High-Dose eye treatment
- New eye drug faricimab tested for blinding disease
- New eye drug trial aims for safer wet AMD treatment